Previous studies have shown that BET degraders inhibited c-Myc in breast cancer and prostate cancer cells, and that p53 was involved in the anticancer activity mediated by BET inhibitor JQ1 in acute myeloid leukemia and medulloblastoma cells17,18. Here, MYC is linked to prostate carcinoma.